Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.81 +2.60%

+$0.88 today

Market cap
$4.84B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 2.71M

Average 2.15M

COGT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Cogent Biosciences, Inc.NASDAQ: COGT

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 171.01M shares rose 50.1% year over year, ahead of the +43.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +39.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +50.1% holds above the trailing-twelve-month pace of +43.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
171.01M+0.1% QoQ
Last fiscal yearDec 2025
160.98M+45.7% YoY
LTMJun 2026
160.65M+43.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.1%——
1 year+45.7%——
3-year CAGR+39.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
160.98M USD
Year-over-year change
+45.7%
4-year CAGR
+42.8%

Weighted Avg Shares vs competitors

How COGT compares with its peers on the latest reported figures

  • COGT's LTM Jun 2026 weighted avg shares of 160.65M shares is the 2nd highest of the 10 companies compared; the peer median is 88.85M shares.
  • Its year-over-year change of +43.3% is the highest of 10, against a peer median of +6.5%.
  • Over three fiscal years its annual growth of +39.9% compares with a peer median of +9.8%.
COGT Competitors Peer median
Weighted Avg Shares for COGT and competitors
Company Period LTM YoY 3-year CAGR
INCYIncyte CorporationLTM Jun 2026198.21M +2.5%-4.2%
COGTCogent Biosciences, Inc.LTM Jun 2026160.65M +43.3%+39.9%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +20.1%+14.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.85M +4.6%+28.8%
KURAKura Oncology, Inc.LTM Mar 202687.97M +1.1%+9.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding COGT) 88.85M+6.5%+9.8%

Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.62M
Gross Profit0000(4.62M)
Gross Margin—————
Research & Development55.91M121.63M173.76M232.66M269.78M
Selling, General & Admin19.64M26.21M34.38M43.28M63.58M
Operating Expenses75.55M147.84M208.13M275.94M328.74M
Depreciation & Amortization147K5.88M3.59M4.35M4.58M
EBITDA(72.13M)(130.37M)(188.82M)(251.51M)(321.29M)
EBITDA Margin—————
Operating Income(75.55M)(147.84M)(208.13M)(275.94M)(333.36M)
Operating Margin—————
Interest Income467K3.99M13.08M18.09M14.69M
Interest Expense03.99M003.06M
Other Income / Expenses3.28M7.6M15.72M20.08M4.43M
Income Before Tax(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Net Margin—————
EPS (Basic)(1.85)(2.26)(2.42)(2.32)(2.04)
EPS (Diluted)(1.85)(2.26)(2.42)(2.32)(2.04)
Weighted Avg Shares38.73M58.74M79.66M110.46M160.98M
Weighted Avg Shares (Diluted)38.73M58.74M79.66M110.46M160.98M

Cogent Biosciences, Inc.

NASDAQ:COGT

Intrinsic Alpha fair value

Locked

Current Price

$27.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.